Marseille Immunopôle (Marseille Immunology Center) has the potential to provide precious help to open new diagnostic and therapeutic pathways and to provide our patients with even more options.
In a few years, immunotherapy has revolutionized the care of patients with bronchial carcinomas. Some patients benefit from long-term control of their disease, and the tolerability for these treatments is far better than for chemotherapy. However, some questions remain unanswered, such as the interaction of these new drugs with other anti-cancer therapies like radiotherapy or radiosurgery, or the limited efficacy of immunotherapy in certain patient populations, like those confronted with brain metastases from primary bronchial carcinoma.
I am a pneumologist-oncologist and I work at the AP-HM in the Multidisciplinary Oncology and Therapeutic Innovations Department at Hôpital Nord, and at the Marseille Oncology Early Testing Center at Hôpital de La Timone, headed by Prof Barlesi. These two departments opened recently and their aim is to improve the care of patients with cancer, notably by providing them with earlier access to the best in therapeutic innovation. I am personally in charge of developing the clinical aspect of translational research in thoracic oncology, in collaboration with Dr Mascaux who is in charge of the biological aspect. A part of our research work is dedicated to these unanswered questions, again, with the aim of quickly transferring the results obtained to the patient’s bedside.
In this context, Marseille Immunopôle (Marseille Immunology Center) has the potential to provide precious help to open new diagnostic and therapeutic pathways and to provide our patients with even more options.#clinic
MI is a diamond of the new Metropolis, offering a unique opportunity to drive science forward and provide more effective therapeutic options for our cancer patients.
MI should enable us to accelerate discovery, enhance our treatment options and offer more innovative options to our patients through current clinical trials and those of the future.
This is the DNA of the cluster to feed local excellence, including, of course, fundamental and applied immunology, and to support the emergence of sector initiatives with strong potential.
Each year, a large number of clinical trials are conducted by APHM clinicians alone or in partnership with industry players in biopharmaceuticals.
AMU, AP-HM, CIML